Genetic testing is changing how HIV regimens are chosen
Pharmacogenetics has moved HIV treatment closer to individualized prescribing, where a patient’s DNA can shape the choice, dose, and safety profile of antiretroviral therapy. In a field defined by lifelong treatment and narrow tolerance for avoidable toxicity, even a single inherited variant can alter adherence, efficacy, and the probability of a serious adverse reaction. The review in Pharmacogenomics focuses on the most clinically established gene-drug pairs in HIV care and maps them to regulatory labels and dosing guidance from major clinical groups.
For clinicians, the practical message is straightforward: genetic testing is no longer an abstract research tool when it comes to certain antiretrovirals. It already changes prescribing decisions for some patients, and the evidence base for selected biomarkers is mature enough to be embedded in routine care. The challenge lies in extending that precision beyond the best-known markers and beyond the populations that have historically dominated genomic research.
HLA-B*57:01 remains the clearest example of prevention before harm
Among all HIV pharmacogenetic markers, HLA-B*57:01 stands out as the most established. Screening for this variant before abacavir exposure reduces the risk of the hypersensitivity reaction that can make the drug dangerous for susceptible patients. In bedside terms, this is one of the most concrete examples of pharmacogenetics preventing an avoidable, potentially life-threatening toxicity before the first tablet is swallowed.
The biology is clinically elegant and unforgiving. Abacavir hypersensitivity is immunologically mediated, and the presence of HLA-B*57:01 identifies a patient in whom immune recognition of the drug can trigger a severe reaction. Because the syndrome can present with fever, rash, gastrointestinal symptoms, and systemic illness, prevention matters more than post hoc management. Once the diagnosis is missed, rechallenge can be hazardous.
Routine HLA-B*57:01 screening has therefore become one of the clearest operational successes in precision HIV medicine. It is the rare biomarker that translates directly into a yes-or-no prescribing decision, with little ambiguity and a strong safety rationale.
UGT1A1 testing helps explain bilirubin elevations and dosing decisions
The review also places UGT1A1 in the center of clinical decision-making for atazanavir and dolutegravir. This gene influences bilirubin metabolism, and variants can predispose patients to bilirubin elevations that may be mistaken for liver injury or may undermine acceptance of treatment because of visible jaundice. In practice, the finding matters because adherence can falter when a patient interprets benign drug-related jaundice as evidence of harm.
Atazanavir has long been associated with unconjugated hyperbilirubinemia, and UGT1A1 variation helps explain why some patients develop more pronounced bilirubin changes than others. The same gene has also been linked in guidance discussions for dolutegravir, reflecting the broader move toward anticipating tolerability issues before they affect continuation. The review ties these associations to regulatory annotations and clinical recommendations, reinforcing that genotype can help separate expected pharmacology from true toxicity.
A visible side effect can become a hidden adherence problem.
That is why this marker has relevance far beyond laboratory interpretation. A patient who stops therapy because of yellowing of the eyes or a clinician who misreads a benign bilirubin rise as hepatic injury can derail otherwise effective treatment. Genetic context helps keep the conversation anchored in mechanism rather than assumption.
CYP2B6 variants remain central to efavirenz tolerability
The strongest pharmacogenetic signal for efavirenz involves CYP2B6, the enzyme that helps determine how quickly the drug is metabolized. Variants in this pathway can increase efavirenz exposure and raise the risk of central nervous system adverse effects such as dizziness, abnormal dreams, and sleep disturbance. These effects are more than an inconvenience; they can interfere with long-term adherence in a therapy area where persistence is essential.
The review frames CYP2B6-guided prescribing as part of a broader effort to reduce the gap between drug exposure and patient tolerance. Efavirenz has a long history in HIV treatment, and its adverse-effect profile has been one of the reasons clinicians sought more individualized approaches. Pharmacogenetics offers a mechanism to explain why two patients on the same regimen can experience very different neurologic tolerability.
In a disease treated across decades rather than weeks, the cumulative impact of manageable but persistent side effects can be substantial. A regimen that is virologically effective but poorly tolerated is not truly effective if it leads to discontinuation, dose frustration, or repeated switching. Genetic guidance gives clinicians a way to anticipate that risk before symptoms become entrenched.
Regulatory labels and dosing guidelines are making precision HIV care operational
A central strength of the review is its focus on implementation rather than theory. It draws on pharmacogenomic databases and on labeling and guidance from the FDA, EMA, Swissmedic, Health Canada, PMDA, CPIC, and DPWG. That mix matters because HIV pharmacogenetics now lives at the intersection of evidence synthesis, regulatory annotation, and local prescribing practice.
Guidelines do more than confirm a gene-drug association. They help define when testing should occur, how results should be interpreted, and whether a dose change, drug avoidance strategy, or alternative regimen is appropriate. For clinicians, those details determine whether pharmacogenetics remains an academic concept or becomes part of everyday prescribing.
The review also makes clear that evidence strength is uneven across markers. HLA-B*57:01 has the broadest real-world adoption, while other markers face practical barriers that slow implementation. Those barriers are not purely scientific. They include test availability, workflow integration, reimbursement, and the need for clearer representation of diverse populations in the underlying data.
Underrepresentation in genomic data still limits how broadly these tools can be used
One of the most consequential issues raised by the review is the uneven ancestry representation in pharmacogenetic research. African and Latin American populations remain underrepresented in much of the genomic evidence that informs current practice. That gap affects both the confidence clinicians can place in some associations and the generalizability of current dosing recommendations.
Precision medicine only works when the evidence base reflects the people receiving treatment. HIV care is global, and the burden of disease is not confined to the populations most often used to build pharmacogenomic datasets. When research coverage is narrow, clinicians may end up applying guidance that is less certain in the very communities that could benefit most from safer prescribing.
This is not a theoretical equity concern. It affects test interpretation, local policy, and patient trust. If a genetic marker is validated mainly in one ancestry group, clinicians need to know whether the same effect size, allele frequency, and clinical relevance hold elsewhere. Without that clarity, the promise of personalization risks becoming unevenly distributed.
Precision HIV prescribing now depends on more than viral suppression
HIV treatment is no longer judged only by whether a regimen suppresses the virus. Safety, tolerability, and the ability to sustain therapy over time are just as important, and pharmacogenetics helps address all three. The review positions HLA-B*57:01, UGT1A1, and CYP2B6 as the most actionable markers in current care, with regulatory and guideline support that makes them clinically usable.
The remaining obstacle is not whether genetic variation matters. It is how quickly systems can make testing routine, how well clinicians can interpret results, and how much of the world’s patient population is represented in the data that drive those decisions. Until those gaps narrow, precision HIV care will remain partly implemented and unevenly shared.